Find a Trial

Trial Results


135 protocol(s) meet the specified criteria
1381-0009OPEN TO ACCRUAL
1808097542OPEN TO ACCRUAL
Racial Disparities in Curative Therapies for Hepatocellular Carcinoma
1811529718OPEN TO ACCRUAL
Introducing Palliative Care (PC) within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial
20170543OPEN TO ACCRUAL
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100).
2018-0877OPEN TO ACCRUAL
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
207497OPEN TO ACCRUAL
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma DREAMM-6
516-003OPEN TO ACCRUAL
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma
9812-11OPEN TO ACCRUAL
Laboratory Studies of Peripheral Blood and Bone Marrow Cells Isolated from Patients with Clonal Myeloid or Lymphoproliferative Disorders
A021502OPEN TO ACCRUAL
RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR
ARO-021OPEN TO ACCRUAL
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
ASTX727-03OPEN TO ACCRUAL
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
BL007OPEN TO ACCRUAL
A Rollover Study to Follow the Durability of Response for Patients from Study UT001 (Formerly TC-UT-03, Post-marketing Commitment) and Study TC-BC-12
BLCCOPEN TO ACCRUAL
Blue Light Cystoscopy with Cysview (BLC with Cysview) Registry
BMTCTN1702OPEN TO ACCRUAL
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)
BTCRC-AML17-113OPEN TO ACCRUAL
Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
BTCRC-LUN17-127OPEN TO ACCRUAL
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
C16-174OPEN TO ACCRUAL
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CC06-C-0213OPEN TO ACCRUAL
Tissue Procurement Protocol for the Development Therapeutics Clinic, National, Cancer Institution (NCI)
CTO-17-101OPEN TO ACCRUAL
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
CTO-20180144OPEN TO ACCRUAL
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
CTO-20190135OPEN TO ACCRUAL
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
CTO-208887OPEN TO ACCRUAL
A Phase I/II Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM5
CTO-A011801OPEN TO ACCRUAL
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
CTO-A031704OPEN TO ACCRUAL
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
CTO-ALLOVIR-P-105-202OPEN TO ACCRUAL
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Viralym-M Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
CTO-AT148002OPEN TO ACCRUAL
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS)
CTO-BMTCTN1705OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
CTO-BRE18-334OPEN TO ACCRUAL
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
CTO-BTCRC-BRE18-337OPEN TO ACCRUAL
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
CTO-BTCRC-GI15-067OPEN TO ACCRUAL
A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma
CTO-BTCRC-GI20-457OPEN TO ACCRUAL
A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial)
CTO-BTCRC-LUN18-153OPEN TO ACCRUAL
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
CTO-BTCRC-LUN19-396OPEN TO ACCRUAL
A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm), IIA, IIB, and select IIIA [T3N1-2, T4N0-2] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA)
CTO-CAEL101-301OPEN TO ACCRUAL
CTO-CAEL101-302OPEN TO ACCRUAL
CTO-CLR-15-03OPEN TO ACCRUAL
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
CTO-CTMX-2009-002OPEN TO ACCRUAL
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-EA2186OPEN TO ACCRUAL
CTO-EAZ171OPEN TO ACCRUAL
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
CTO-FGCL-3019-087OPEN TO ACCRUAL
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
CTO-GOG-3053OPEN TO ACCRUAL
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
CTO-IUSCC-0701OPEN TO ACCRUAL
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy
CTO-IUSCC-0715OPEN TO ACCRUAL
Pilot study of a mobile health strategy to improve medication adherence in breast cancer survivors receiving aromatase inhibitors
CTO-IUSCC-0718OPEN TO ACCRUAL
A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention program
CTO-IUSCC-0722OPEN TO ACCRUAL
Circulating tumor DNA as a predictive biomarker to individualize therapy in patients with stage III non-small cell lung cancer
CTO-IUSCC-0723OPEN TO ACCRUAL
Evaluating the incidence and outcomes of patients with stage III non-small cell lung cancer (NSCLC) whose tumors harbor STK11 and/or Keap1 mutations treated with chemoradiation (CRT) followed by consolidation immunotherapy
CTO-IUSCC-0726OPEN TO ACCRUAL
Significance of STK11/LKB1 or Keap1 mutations in Stage III Non-Small Cell Lung Cancer
CTO-IUSCC-0729OPEN TO ACCRUAL
Non-coding mutations in Multiple Myeloma
CTO-IUSCC-0730OPEN TO ACCRUAL
A Basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1
CTO-IUSCCC-0742OPEN TO ACCRUAL
Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor
CTO-IUSCCC-0752OPEN TO ACCRUAL
A phase II trial evaluating the efficacy of Cabozantinib in the treatment of incurable patients with refractory germ cell tumors
CTO-IUSCCC-0759OPEN TO ACCRUAL
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
CTO-JAB-3312-1003OPEN TO ACCRUAL
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination with Pembrolizumab or Binimetinib in Adult Patients with Advanced Solid Tumors
CTO-LOXO-IDH-20002OPEN TO ACCRUAL
A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations
CTO-LUN18-335OPEN TO ACCRUAL
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
CTO-MK-3475-866OPEN TO ACCRUAL
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
CTO-MK-3475-905OPEN TO ACCRUAL
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
CTO-MK-3475-937OPEN TO ACCRUAL
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
CTO-NCICOVIDOPEN TO ACCRUAL
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
CTO-PRE0405OPEN TO ACCRUAL
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
CTO-R5458-ONC-1826OPEN TO ACCRUAL
A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
CTO-S1823OPEN TO ACCRUAL
A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORS
CTO-SNDX-6352-0504OPEN TO ACCRUAL
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
CTO-TAK-981-1503OPEN TO ACCRUAL
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
CTO-UF-STO-PANC-004OPEN TO ACCRUAL
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
DERM-IIR-DFSPOPEN TO ACCRUAL
Dermatofibrosarcoma Protrubrans (DFSP) treated with Mohs Micrographic Surgery: Risk Factors and Treatment Outcomes.
EA4151/BMTCTN1601OPEN TO ACCRUAL
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
ECRO-CELGENE-BB2121-EAP-001OPEN TO ACCRUAL
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
GI-CPDPC-MATHER-DETECTOPEN TO ACCRUAL
CPDPC 16-04: Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT)
GI-CREATICS-CRTX1-201OPEN TO ACCRUAL
Prospective Collection of Colon Lavage Fluids for Pancreatic Cancer Marker Validation
INCB39110-309OPEN TO ACCRUAL
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUCRO-0309OPEN TO ACCRUAL
IU Pancreatic Lesion Tissue/Fluid Bank
IUCRO-0370OPEN TO ACCRUAL
Pathobiology of Paget's Disease
IUCRO-0476OPEN TO ACCRUAL
A Study of the Effect of Sirolimus Levels on Incidence of Hepatic Sinusoidal Obstructive Syndrome
IUCRO-0495OPEN TO ACCRUAL
Creation of a Pancreatic Cancer Outcome Database with Blood Storage
IUSCC-0523OPEN TO ACCRUAL
Perioperative pelvic floor muscle training may improve recovery of continence in men with localized prostate cancer undergoing robot-assisted radical prostatectomy.
IUSCC-0567OPEN TO ACCRUAL
Circulating Tumor Cells (CTC) in Lung Cancer
IUSCC-0579OPEN TO ACCRUAL
Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0605OPEN TO ACCRUAL
Evaluating dose de-escalation in whole brain radiation therapy with simultaneous integrated boost for patients with brain metastases
IUSCC-0608OPEN TO ACCRUAL
T-Cell Leukemia/Lymphoma Biorepository
IUSCC-0611OPEN TO ACCRUAL
Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University
IUSCC-0627OPEN TO ACCRUAL
A Phase II Study Analyzing Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients with 1 4 Brain Metastases
IUSCC-0628OPEN TO ACCRUAL
Long-Term Adverse Health Outcomes in Survivors of Germ Cell Tumors Treated with High Dose Chemotherapy
IUSCC-0630OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY AND REGISTRY FOR INFLAMMATORY BREAST CANCER
IUSCC-0633OPEN TO ACCRUAL
Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery
IUSCC-0639OPEN TO ACCRUAL
Comparative analysis of biodynamic imaging utility in predicting response to gemcitabine chemotherapy for human and canine mycosis fungoides
IUSCC-0645OPEN TO ACCRUAL
Description of Cardiotoxicity Associated with Sunitinib in Renal Cell Carcinoma
IUSCC-0649OPEN TO ACCRUAL
Functional and Neurochemical Substrates of Chemotherapy-Related Cognitive Deficits
IUSCC-0658OPEN TO ACCRUAL
The Role of 68Ga-PSMA-11 PET in MRI Fusion Biopsy and Surgery Guidance in Prostate Cancer
IUSCC-0659OPEN TO ACCRUAL
Assessing tobacco use and cessation support among patients with non-tobacco related cancers
IUSCC-0661OPEN TO ACCRUAL
The Indiana Myeloma Registry
IUSCC-0662OPEN TO ACCRUAL
A pilot study evaluating the feasibility and safety of a fasting-mimicking diet in patients receiving systemic treatment for metastatic non-small cell lung cancer
IUSCC-0669OPEN TO ACCRUAL
Evaluating Different Methods of Circulating Tumor DNA Quantification in Oncology Patients
IUSCC-0670OPEN TO ACCRUAL
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting as a Potential Teachable Moment for Actively Smoking Family Members
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0688OPEN TO ACCRUAL
A Retrospective Tissue Analysis of NQO1 Status in Patients with Germ Cell Tumors
IUSCC-0690OPEN TO ACCRUAL
Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer Center
IUSCC-0708OPEN TO ACCRUAL
Genomic Analysis of Relapsed/Refractory Germ-Cell Tumors
IUSCC-0709OPEN TO ACCRUAL
Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical Trials
J11155OPEN TO ACCRUAL
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
NURS-IIR-IUSCC-0748OPEN TO ACCRUAL
Biobehavioral correlates of cancer-related cognitive dysfunction and its co-occurring symptoms
OTHN-IIR-IUSCC-0685OPEN TO ACCRUAL
Characterization of Cachexia in Tissues from Head and Neck Surgery Patients Receiving Free Flap Reconstruction.
OTHN-IIR-IUSCC-0733OPEN TO ACCRUAL
Functional and Molecular Analysis of Muscle in Patients With and Without Head and Neck Cancer Cachexia
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PSY-IIR-IUSCC-0698OPEN TO ACCRUAL
Telephone Support for Metastatic Breast Cancer Patients
PULM-IIR-DRCOPEN TO ACCRUAL
Analysis of DRC in lung disease
RADY-ECOG-WESTPHAL-EA1151OPEN TO ACCRUAL
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
RADY-IIR-CBTOPEN TO ACCRUAL
Mobile Device CBT for Chemotherapy-Related Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial
RADY-IUSCC-0725OPEN TO ACCRUAL
Yttrium-90 Radiation Segmentectomy versus Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Early Stage Hepatocellular Carcinoma (HCC): A Pilot Study
RAON-IIR-IUSCC-0711OPEN TO ACCRUAL
Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients with Lung Tumors in Close Proximity to the Chest Wall
RAON-IIR-IUSCC-0745OPEN TO ACCRUAL
A Prospective Pilot Trial Evaluating a 3D Printed Oral Stent Device with Suction for Oral Cancer Radiation Treatment
RAON-STANFORD-AVATAROPEN TO ACCRUAL
AVATAR anesthesia alternative in pediatric radiotherapy: A Multi-Center Pilot Study
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
STU00077147OPEN TO ACCRUAL
Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer
SURG-BOSTONSC-E7107OPEN TO ACCRUAL
Intra-operative Pancreatoscopy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN)
SURG-DAVOL-PREVENTOPEN TO ACCRUAL
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy
SURG-IIR-COVID-19-RESPONSEOPEN TO ACCRUAL
Impact of the Initial COVID-19 Response and the Following Delayed Care Surge on Patients Requiring Emergent, Urgent, and Elective Surgical Procedures
SURG-IIR-CTDNAOPEN TO ACCRUAL
A phase I feasibility study to identify circulating tumor DNA in patients with Barrett's epithelium and early stage esophageal adenocarcinoma treated with endoscopic mucosal resection
SURG-TAKEDA-954-2004OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection
TBCRC034OPEN TO ACCRUAL
The incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in patients diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy
TBCRC042OPEN TO ACCRUAL
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
UROL-CC-IUSCCC-0760OPEN TO ACCRUAL
The Role of 68Ga-PSMA-11 PET in Surgery Guidance in Prostate Cancer: A prospective Pilot trial